# Novartis AG (NVS)

> Source: Nexqual · https://nexqual.com/NVS · data as of 2026-10-22 20:00 UTC · cite as "Nexqual, Novartis AG (NVS), nexqual.com/NVS" · informational, not investment advice.

**Price:** USD 156.27 (+1.52% on the day) · last close of Oct 22, 2026; US market pre market, not a live price. Prev close 153.93 · day 154.38–157.1 · 52w 121.57–170.46 · market cap $297B · NYQ

## Key facts
- 5 of 80 tracked superinvestors hold NVS (13F, Q2 2026): 0 new, 2 added, 2 reduced, 1 unchanged.
- Analysts: Hold (mean 2.58 on a 1–5 scale) (12 analysts), mean target USD 154.65 (range 130–185).
- Total return with dividends: 1Y +22.3% vs S&P 500 +14.9%; 5Y +121.9% vs S&P 500 +80.3%.
- Next earnings: 2026-10-27, EPS estimate USD 2.24, revenue estimate $14.6B.

## Superinvestors (SEC 13F-HR, Q2 2026)
5 of 80 tracked investors hold NVS. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Tweedy Browne |  | 0.84% | $11.1M | Reduced -0.3% |
| Kahn Brothers | Kahn Brothers Group | 0.36% | $2.0M | Unchanged |
| Dodge & Cox Funds | Dodge & Cox | 0.06% | $119M | Reduced -89.1% |
| Lee Ainslie | Maverick Capital | 0.04% | $4.4M | Added +82.3% |
| Sarah Ketterer | Causeway Capital Management | <0.01% | $235K | Added +0.9% |

## Analysts
Consensus Hold (mean 2.58 on a 1–5 scale), 12 analysts; mean target USD 154.65 (low 130, high 185).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-10 | HSBC | Upgrade | Reduce → Hold | $123 → $136 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-23) | 5Y (from 2021-10-18) |
|---|---|---|
| Total return | +22.3% | +121.9% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +22.4% | +17.2% |
| Volatility (annualized) | 27.3% | 20.8% |
| Max drawdown | -16.2% (Feb 2026→Sep 2026) | -19.7% (Aug 2024→Dec 2024) |

## Peers (Drug Manufacturers - General)
AZN (AstraZeneca PLC) USD 172.57 +2.45% · MRK (Merck & Company, Inc.) USD 147.24 -1.76% · AMGN (Amgen Inc.) USD 447.28 +2.04% · GILD (Gilead Sciences, Inc.) USD 157.19 +2.36% · ABBV (AbbVie Inc.) USD 285.19 +0.14% · NVO (Novo Nordisk A/S) USD 39.43 +0.95%

## More
Full page: https://nexqual.com/NVS · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Supply chain and relationships (SEC annual reports)


Other companies that name NVS in their own reports (relationship from NVS's side):

| Relationship | Company | Their filing | Sentence |
|---|---|---|---|
| partner | Cellectis S.A. (CLLS) | 20-F 2026-03-20 | "Autologous and Allogeneic CAR T-cell space: Bristol-Myers Squibb, Gilead Sciences Inc., Novartis AG, Johnson & Johnson, Regeneron Pharmaceuticals Inc., Fate Therapeutics Inc., CRISPR Therapeutics Inc.…" |
| partner | Mereo BioPharma Group plc (MREO) | 10-K 2026-03-19 | "We have strong relationships with these companies, as evidenced by our agreements with Novartis AG ("Novartis") and AstraZeneca AB ("AstraZeneca"), as well as our partnership with Ultragenyx, and a tr…" |
| partner | Monte Rosa Therapeutics, Inc. (GLUE) | 10-K 2026-03-17 | "the potential benefits of strategic collaborations and our ability to enter into strategic collaborations with third parties who have the expertise to enable us to further develop our biological targe…" |
| supplier | Rallybio Corp (RLYB) | 10-K 2026-03-16 | "Prior to Novartis, Ms. Boudreau served in roles of increasing responsibility in strategy and finance at Pfizer Inc. ("Pfizer") from April 1999 to September 2008, including Vice President Finance Custo…" |
| partner | MOLECULAR PARTNERS AG (MOLN) | 20-F 2026-03-12 | "For example in January 2024, Novartis, our collaboration partner for ensovibep, informed us of its decision to return the global rights for ensovibep to us following the end of COVID-19 pandemic." |
| partner | GSK plc (GSK) | 20-F 2026-03-06 | "The consideration payable for the acquisition of the Shionogi-ViiV Healthcare joint venture, Affinivax, the Novartis Vaccines" |
| partner | REGENXBIO Inc. (RGNX) | 10-K 2026-03-05 | "Royalty revenue to date consists primarily of royalties on net sales of Zolgensma and Itvisma, which are licensed products under the Company's license agreement with Novartis Gene Therapies, Inc. (Nov…" |
| partner | Ocugen, Inc. (OCGN) | 10-K 2026-03-04 | "We are aware of several companies focusing on gene therapies for various ophthalmic indications including Applied Genetic Technologies Corporation, as acquired by Beacon Therapeutics, Astellas Pharma …" |
| partner | Arcus Biosciences, Inc. (RCUS) | 10-K 2026-02-25 | "There are many other companies that have commercialized and/or are developing oncology treatments for cancer including large pharmaceutical and biotechnology companies such as AstraZeneca, BeiGene, Lt…" |
| partner | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | 10-K 2026-02-12 | "Leqvio (inclisiran) is being developed and commercialized by our collaborator Novartis AG, or Novartis, and has received marketing authorization from the European Commission, or EC, for the treatment …" |

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | $2.24 | $2.20 | +1.9% | $14.61B | 3 |
| Next quarter (ends 2026-12-31) | $2.22 | $2.32 | -4.1% | $14.99B | 3 |
| Current fiscal year (ends 2026-12-31) | $8.83 | $8.68 | +1.7% | $57.64B | 9 |
| Next fiscal year (ends 2027-12-31) | $9.80 | $9.75 | +0.5% | $61.32B | 10 |

## Options: expected move (Cboe, 15-min delayed)

Expected move by 2026-11-20 (includes earnings 2026-10-27): ±6.5%.

| Expiration | Days | ATM IV | Expected move |
|---|---|---|---|
| 2026-11-20 | 28 | 28.8% | ±6.5% |
| 2026-12-18 | 56 | 26.6% | ±8.4% |
| 2027-01-15 | 84 | 25.3% | ±9.9% |
| 2027-04-16 | 175 | 26.4% | ±15.2% |
| 2027-06-17 | 237 | 25.1% | ±16.3% |